Endometrial cancer (Homo sapiens)
From WikiPathways
Description
Endometrial cancer (EC) is the most common gynecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
Phosphorylation information collected from PhosphoSitePlus (https://www.phosphosite.org)
Proteins on this pathway have targeted assays available via the CPTAC Assay PortalQuality Tags
Ontology Terms
Bibliography
- Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E; ''PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.''; Nucleic Acids Res, 2015 PubMed Europe PMC Scholia
- Buza N, Roque DM, Santin AD; ''HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.''; Arch Pathol Lab Med, 2014 PubMed Europe PMC Scholia
- Winterhoff B, Konecny GE; ''Targeting fibroblast growth factor pathways in endometrial cancer.''; Curr Probl Cancer, 2017 PubMed Europe PMC Scholia
- Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A; ''Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF.''; Nature, 1991 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Annotated Interactions
No annotated interactions